Prevalence of fosfomycin resistance among ESBL-producing Escherichia coli isolates in the community, Switzerland

Eur J Clin Microbiol Infect Dis. 2019 May;38(5):945-949. doi: 10.1007/s10096-019-03531-0. Epub 2019 Mar 15.

Abstract

Our aim was to evaluate the prevalence of fosfomycin-resistant strains among ESBL-producing Escherichia coli isolates recovered from community patients in Switzerland. A total of 1225 ESBL-producing E. coli isolates were collected between 2012 and 2013 from a private and community laboratory. Fosfomycin resistance was assessed by using the novel rapid fosfomycin/E. coli NP test and agar dilution method. Resistant isolates were further investigated for acquired resistance genes fosA1-7 by PCR and sequencing. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) were performed to evaluate the clonal relationship among fosA3-carrying isolates. Out of the 1225 ESBL-producing E. coli isolates analyzed in this study, 1208 were fosfomycin susceptible while 17 were fosfomycin resistant. No discrepancy was observed between the rapid fosfomycin/E. coli NP test and the agar dilution method taken as the gold standard. Five out of the 17 resistant isolates carried a fosA-like gene. No clonal relationship was observed among those isolates. Here, the prevalence of fosfomycin resistance among ESBL-producing E. coli isolates in the community is reported for the first time in Switzerland, being ca. 1.4%. Among the five isolates carrying a fosA gene, four encoded the FosA3 enzyme, being the most prevalent fosfomycin-resistant determinant. An excellent correlation was observed between minimum inhibitory concentration-based susceptibility categorization and results of the rapid fosfomycin/E. coli NP test, further indicating the excellent sensitivity and specificity of this recently developed rapid test whose results are obtained in less than 2 h.

Keywords: Enterobacterales; Rapid test.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • DNA, Bacterial / genetics
  • Drug Resistance, Multiple, Bacterial* / genetics
  • Escherichia coli / classification
  • Escherichia coli / drug effects*
  • Escherichia coli / enzymology*
  • Escherichia coli / genetics
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Proteins / genetics
  • Fosfomycin / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Molecular Typing
  • Prevalence
  • Sequence Analysis, DNA
  • Switzerland / epidemiology
  • beta-Lactamases / biosynthesis*
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial
  • Escherichia coli Proteins
  • Fosfomycin
  • beta-Lactamases